Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Universal Procon Bags Five New Clients, Plans Asian Expansion
Universal Procon plans to open an office in Singapore to cater to the needs of Asian clients. It will initially employ four staff, one a business development manager.
Universal Procon plans to open an office in Singapore to cater to the needs of Asian clients. It will initially employ four staff, one a business development manager.
The new location features a microfabrication facility, custom-designed laboratories for the company’s research and development, and manufacturing space for commercial operations. IntegenX expects to use the in-house microfabrication
CytRx expects to enroll up to 50 patients with metastatic hormone-refractory prostate cancer who have failed first-line therapy with either the chemotherapy agent docetaxel or mitoxantrone in this
Machaon’s FDA-approved array-based technology detects genetic variations in 2 key genes involved in the metabolism of warfarin. 40% of the general population in the US are said to
Terrance Owen, president and CEO, said: “Receiving the NDC number from the FDA provides Aldawith the consent that is needed to introduce our products in the US. This
OrbiMed said that the Israeli team is expected to collaborate closely with its global team of nearly 40 professionals to invest in companies across all stages of development.
According to JR Vyas, managing director of the company, the planned finances would help fund the manufacturing facilities. The four new proposed plants, scheduled to open 15 months
The products help to prevent the transmission of blood-borne diseases such as HIV and hepatitis C via needlestick injuries, aerosol dispersal and syringe reuse. Primary target markets of
SAFC said that the new facility complements its existing 63,000 sq ft HPAPI site in Madison and houses commercial scale reactors capable of producing HPAPI batch sizes up
BioAlliance Pharma is expected to receive up to EUR48.5m from Therabel, of which EUR6.5m as upfront payments including EUR4.5m at signature and two annual payments of EUR1m each